ICD risk stratification studies – EU-CERT-ICD and the European perspective

Journal of Electrocardiology

Volumn 49, Issue 6, 2016, Pages 831-836

  Seegers, Joachim ^a,b   Bergau, Leonard ^a   Tichelbäcker, Tobias ^a   Malik, Marek ^c   Zabel, Markus ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Cardioverter defibrillator, implantable; Mortality; Risk factors; Sudden cardiac death

Indexed keywords

ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL DECISION MAKING; COMPARATIVE EFFECTIVENESS; CONGESTIVE CARDIOMYOPATHY; EUROPE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH VOLUME HOSPITAL; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LOW RISK PATIENT; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STRATIFIED SAMPLE; ADULT; AGED; CAUSALITY; COMORBIDITY; EUROPEAN UNION; EVIDENCE BASED MEDICINE; FEMALE; HEART FAILURE; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICS AND NUMERICAL DATA; SUDDEN CARDIAC DEATH; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UTILIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CAUSALITY; COMORBIDITY; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; EUROPE; EUROPEAN UNION; EVIDENCE-BASED MEDICINE; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84994097188     PISSN: 00220736     EISSN: 15328430     Source Type: Journal    
DOI: 10.1016/j.jelectrocard.2016.08.011     Document Type: Article

References (21)

1. [1] Moss, AJ, Zareba, W, Hall, WJ, Klein, H, Wilber, DJ, Cannom, DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002), 877–883.
2. [2] Bardy, GH, Lee, KL, Mark, DB, Poole, JE, Packer, DL, Boineau, R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005), 225–237.
3. [3] Hartley, A, Marshall, DC, Salciccioli, JD, Sikkel, MB, Maruthappu, M, Shalhoub, J, Trends in Mortality From Ischemic Heart Disease and Cerebrovascular Disease in Europe: 1980 to 2009. Circulation 133 (2016), 1916–1926.
4. [4] Pitt, B, Reichek, N, Willenbrock, R, Zannad, F, Phillips, RA, Roniker, B, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108 (2003), 1831–1838.
5. [5] Kastrati, A, Dibra, A, Spaulding, C, Laarman, GJ, Menichelli, M, Valgimigli, M, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 28 (2007), 2706–2713.
6. [6] Moss, AJ, Schuger, C, Beck, CA, Brown, MW, Cannom, DS, Daubert, JP, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 367 (2012), 2275–2283.
7. [7] Seegers, J, Conen, D, Jung, K, Bergau, L, Dorenkamp, M, Lüthje, L, et al. Sex difference in appropriate shocks but not mortality during long-term follow-up in patients with implantable cardioverter-defibrillators. Europace 18 (2016), 1194–1202.
8. [8] Fauchier, L, Marijon, E, Defaye, P, Piot, O, Sadoul, N, Perier, M-C, et al. Effect of age on survival and causes of death after primary prevention implantable cardioverter-defibrillator implantation. Am J Cardiol 115 (2015), 1415–1422.
9. [9] MacFadden, DR, Crystal, E, Krahn, AD, Mangat, I, Healey, JS, Dorian, P, et al. Sex differences in implantable cardioverter-defibrillator outcomes: findings from a prospective defibrillator database. Ann Intern Med 156 (2012), 195–203.
10. [10] Lee, DS, Hardy, J, Yee, R, Healey, JS, Birnie, D, Simpson, CS, et al. Clinical Risk Stratification for Primary Prevention Implantable Cardioverter Defibrillators. Circ Heart Fail 8 (2015), 927–937.
11. [11] Raatikainen, MJP, Arnar, DO, Zeppenfeld, K, Merino, JL, Levya, F, Hindriks, G, et al. Statistics on the use of cardiac electronic devices and electrophysiological procedures in the European Society of Cardiology countries: 2014 report from the European Heart Rhythm Association. Europace 17:Suppl. 1 (2015), i1–75.
12. [12] Ranasinghe, I, Parzynski, CS, Freeman, JV, Dreyer, RP, Ross, JS, Akar, JG, et al. Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation: An Observational Cohort Study. Ann Intern Med, 2016.
13. [13] Elliott, PM, Anastasakis, A, Borger, MA, Borggrefe, M, Cecchi, F, Charron, P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35 (2014), 2733–2779.
14. [14] Koller, MT, Schaer, B, Wolbers, M, Sticherling, C, Bucher, HC, Osswald, S, Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study. Circulation 117 (2008), 1918–1926.
15. [15] Goldenberg, I, Vyas, AK, Hall, WJ, Moss, AJ, Wang, H, He, H, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 51 (2008), 288–296.
16. [16] Levy, WC, Lee, KL, Hellkamp, AS, Poole, JE, Mozaffarian, D, Linker, DT, et al. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation 120 (2009), 835–842.
17. [17] Seegers, J, Vos, MA, Flevari, P, Willems, R, Sohns, C, Vollmann, D, et al. Rationale, objectives, and design of the EUTrigTreat clinical study: a prospective observational study for arrhythmia risk stratification and assessment of interrelationships among repolarization markers and genotype. Europace 14 (2012), 416–422.
18. [18] Bergau, L, Willems, R, Tuinenburg, A, Vos, MA, Flevari, P, Sohns, C, et al. Risk stratification of ICD patients for appropriate shock and mortality in a multi-centre cohort. The EU-TrigTreat study. Eur Heart J 36 (2015), 8–9 [P165].
19. [19] Ellenbogen, KA, Levine, JH, Berger, RD, Daubert, JP, Winters, SL, Greenstein, E, et al. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?. Circulation 113 (2006), 776–782.
20. [20] Luermans, JGLM, Mafi Rad, M, Vernooy, K, A call for re-evaluation of the guidelines for prophylactic ICD implantation. Neth Heart J 22 (2014), 429–430.
21. [21] Providência, R, Marijon, E, Lambiase, PD, Bouzeman, A, Defaye, P, Klug, D, et al. Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women-Data From a Multicenter French Registry. J Am Heart Assoc, 2016, 5.